Tenon Medical (TNON) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $0.89 million, down 6% year-over-year and 1.6% sequentially, while nine-month revenue grew 18% to $2.51 million, driven by a 5% increase in Catamaran system procedures year-to-date.

• Gross margin for Q3 was 47% (down from 57% in Q3 2023), but nine-month gross margin improved to 54% from 32% year-over-year.

• Net loss for Q3 was $3.18 million, an improvement from $3.33 million in Q3 2023; nine-month net loss narrowed to $10.59 million from $12.6 million.

• Balance sheet strengthened with $9.6 million in net proceeds from equity financings, bringing cash and equivalents to $9.2 million as of September 30, 2024, with no outstanding debt.

• Launched Catamaran SE, a smaller implant version, with positive initial physician feedback and full commercial launch planned for early 2025.

Financial highlights

• Q3 2024 revenue: $0.89 million (down 6% YoY); nine-month revenue: $2.51 million (up 18% YoY).

• Q3 gross profit: $418,000 (47% margin); nine-month gross profit: $1.4 million (54% margin).

• Q3 operating expenses: $3.6 million, down from $3.9 million YoY; nine-month operating expenses: $12 million, down from $13.3 million.

• Q3 net loss: $3.18 million; nine-month net loss: $10.59 million, both improved from prior year.

• No outstanding debt as of September 30, 2024.

Outlook and guidance

• Expects coding clarity and new clinical data to resolve reimbursement headwinds and support future revenue growth.

• National launch of Catamaran SE platform expected in early 2025.

• Plans to expand sales force and commercial infrastructure in 2025, leveraging strong balance sheet.

• Management expects continued operating losses and negative cash flows as commercialization and product development continue.

• Existing cash is not sufficient to fund operations for the next 12 months; additional capital will be sought.